Trial Profile
An Expanded Access Protocol for Idelalisib in Combination With Rituximab for Relapsed, Previously Treated Subjects With Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2019
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Gilead Sciences
- 02 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 15 May 2014 New trial record